Ftse Mib
34.825,01
0,00%
DAX
18.768,96
0,33%
S&P 500
5.308,13
0,09%
NASDAQ
16.794,87
0,65%
Bitcoin
71.209,04
-0,34%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Auris Medical Holding AG (EARS) Auris Medical Holding AG (EARS) Notizie

EARS

Auris Medical (EARS)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:EARS
DataOraFonteTitoloSimboloCompagnia
27/06/202322:46Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:EARSAuris Medical Holding AG
16/06/202323:02Edgar (US Regulatory)Securities Registration (foreign Private Issuer) (f-1)NASDAQ:EARSAuris Medical Holding AG
12/06/202312:44Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:EARSAuris Medical Holding AG
09/06/202322:37Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)NASDAQ:EARSAuris Medical Holding AG
27/04/202322:34Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:EARSAuris Medical Holding AG
17/04/202318:22Edgar (US Regulatory)Certification by the Exchange Approving Securities for Listing (cert)NASDAQ:EARSAuris Medical Holding AG
13/04/202314:20Edgar (US Regulatory)Withdrawal of Registration Statement (rw)NASDAQ:EARSAuris Medical Holding AG
11/04/202322:02Edgar (US Regulatory)Securities Registration (section 12(b)) (8-a12b)NASDAQ:EARSAuris Medical Holding AG
11/04/202322:02Edgar (US Regulatory)Free Writing Prospectus - Filing Under Securities Act Rules 163/433 (fwp)NASDAQ:EARSAuris Medical Holding AG
27/03/202316:34Edgar (US Regulatory)Securities Registration (foreign Private Issuer) (f-1/a)NASDAQ:EARSAuris Medical Holding AG
23/09/202222:32Edgar (US Regulatory)Securities Registration (foreign Private Issuer) (f-3)NASDAQ:EARSAuris Medical Holding AG
14/04/202222:53Edgar (US Regulatory)Post-effective Amendment to Registration Statement (pos Am)NASDAQ:EARSAuris Medical Holding AG
12/04/202214:02Edgar (US Regulatory)Annual and Transition Report (foreign Private Issuer) (20-f)NASDAQ:EARSAuris Medical Holding AG
08/12/202122:38Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:EARSAuris Medical Holding AG
16/07/202115:00GlobeNewswire Inc.Auris Medical Announces Launch of New Corporate WebsiteNASDAQ:EARSAuris Medical Holding AG
14/07/202115:00GlobeNewswire Inc.Auris Medical Announces Publication of Data from Preclinical Studies with Bentrio™ Nasal Spray in Prevention and Mitigation...NASDAQ:EARSAuris Medical Holding AG
06/07/202115:00GlobeNewswire Inc.Auris Medical to Develop KRAS-Targeting RNA Treatment for Colorectal Cancer as First Therapeutic Indication for OligoPhore™...NASDAQ:EARSAuris Medical Holding AG
28/06/202114:30GlobeNewswire Inc.Auris Medical to Initiate Market Launch of Bentrio™ Nasal Spray in GermanyNASDAQ:EARSAuris Medical Holding AG
21/06/202114:30GlobeNewswire Inc.Auris Medical Announces Significant Inhibition of Tumor Growth with OligoPhore siRNA Targeting NF-κB in Murine Model of Adul...NASDAQ:EARSAuris Medical Holding AG
03/06/202113:30GlobeNewswire Inc.Auris Medical Announces Acquisition of RNA Therapeutics Company and Plans for Strategic RepositioningNASDAQ:EARSAuris Medical Holding AG
01/06/202114:30GlobeNewswire Inc.Auris Medical Starts Preparations for Covid-19 Trial with Bentrio in IndiaNASDAQ:EARSAuris Medical Holding AG
28/05/202114:30GlobeNewswire Inc.Auris Medical Holding to Present at LD Micro Invitational XI ConferenceNASDAQ:EARSAuris Medical Holding AG
25/05/202115:00GlobeNewswire Inc.Auris Medical Announces Completion of Bentrio Conformity Assessment Procedure for Marketing in EUNASDAQ:EARSAuris Medical Holding AG
14/05/202114:30GlobeNewswire Inc.Auris Medical Reaches Midpoint for Enrollment in Part B of AM-125 Phase 2 TRAVERS Trial in Acute Peripheral VertigoNASDAQ:EARSAuris Medical Holding AG
07/05/202115:05GlobeNewswire Inc.Auris Medical Provides Update on Bentrio Program in AllergyNASDAQ:EARSAuris Medical Holding AG
13/04/202113:45GlobeNewswire Inc.Auris Medical Announces Positive Preclinical and Clinical Outcomes with AM-301 and Details Plans for Market LaunchNASDAQ:EARSAuris Medical Holding AG
08/04/202114:00GlobeNewswire Inc.Auris Medical to Provide Business Update on AM-301 Program on Tuesday, April 13, 2021NASDAQ:EARSAuris Medical Holding AG
31/03/202114:30GlobeNewswire Inc.Auris Medical Provides Business Update and Reports Second Half and Full Year 2020 Financial ResultsNASDAQ:EARSAuris Medical Holding AG
24/03/202113:00GlobeNewswire Inc.Auris Medical to Report Second Half and Full Year 2020 Financial Results and Provide Business Update on Wednesday, March 31, ...NASDAQ:EARSAuris Medical Holding AG
29/01/202114:30GlobeNewswire Inc.Auris Medical Announces Initiation of Clinical Investigation of AM-301 in Allergic RhinitisNASDAQ:EARSAuris Medical Holding AG
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:EARS

La tua Cronologia

BIT
11COV
Covestro
BIT
18TRA
Traton
BIT
19MW
Marvell Technology
BIT
1A
Agilent Technologies
BIT
1AA
Alcoa
BIT
1AAD
Amadeus Fire
BIT
1AAG
Aumann
BIT
1AAL
American Airlines
BIT
1AAPL
Apple
BIT
1ABBV
Abbvie
BIT
1ABI
Anheuser Busch InBev SA NV
BIT
1ABNB
Airbnb
BIT
1ACA
Credit Agricole
BIT
1ACS
ACS Actividades de Const...
BIT
1AD
Koninklijke Ahold Delhai...
BIT
1ADBE
Adobe
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network